The pressure on Novo Nordisk's diabetes portfolio is mounting in the US - and the situation seems even more precarious after its top exec in the region quit.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.